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Abstract
Background: Polysaccharide pneumococcal vaccine is recommended for use in HIV-infected
adults in Brazil but there is uncertainty about its effectiveness in this patient population.
The main objective of this study was to assess the effectiveness of the 23-valent polysaccharide
pneumococcal vaccine against invasive pneumococcal infection among HIV-infected adult patients
in São Paulo, Brazil.
Methods: A case-control study of 79 cases and 242 controls matched on CD4+ cell count and
health care setting was conducted. Among HIV-infected adults in São Paulo, Brazil, with and
without S. pneumoniae recovered from a normally sterile site; prior receipt of 23 valent
polysaccharide pneumococcal vaccine was determined by review of medical records and patient
interview.
Results: After adjustment for confounding factors, the point estimate for the effectiveness of 23
valent polysaccharide vaccine among HIV-infected adults against all invasive pneumococcal infection
was 18% (95% CI: <0 to 62%).
Conclusion: We were unable to demonstrate a statistically significant protective effect of 23
valent polysaccharide against invasive pneumococcal infection vaccine among HIV-infected adults in
Brazil.
While the vaccine is relatively inexpensive and safe, its effectiveness among HIV-infected adults in 
Brazil is uncertain.
Background
It is well-established that HIV-infected individuals are at
increased risk of bacterial pneumonia in general and of
pneumonia due to S. pneumoniae in particular [1,2]. The
incidence of invasive pneumococcal disease (i.e. docu-
mented S. pneumoniae infection of a normally sterile site,
such as blood or cerebrospinal fluid) among HIV-infected
patients not receiving anti-retroviral therapy or antibiotic
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prophylaxis is estimated to be at least 100 times that in the
general population [3-6]. In developing countries, S.
pneumoniae is one of the most common opportunistic
infections and is a leading cause of morbidity and mortal-
ity among HIV-infected adults and children.
Purified pneumococcal polysaccharide vaccines have
been developed and licensed for use in various countries
over the past 25 years. The currently available pneumo-
coccal polysaccharide vaccine contains the 23 serotypes of
S. pneumoniae that collectively account for approxi-
mately 90% of invasive pneumococcal disease in adults in
the United States. This vaccine, which was licensed in the
U.S. in 1983, is recommended for use in HIV-infected
individuals over the age of two years by the Advisory
Committee on Immunization Practices of the U.S. Public
Health Service [7]. Similar recommendations for its use in
HIV-infected individuals exist in Europe, Australia, and
Brazil [8].
Observational studies have produced estimates of the
effectiveness of the 23 valent pneumococcal polysaccha-
ride vaccine against invasive pneumococcal infection in
the range of 30% to 80% among adults with normal
immune function [9-12]. However, among severely
immunosuppressed adults, the polysaccharide vaccine
has little or no protective effect [10]. Studies of the vac-
cine's effectiveness among HIV-infected adults have pro-
duced widely disparate results, perhaps in part due to
varying levels of immunosuppression among the study
populations [13-21]. The only randomized controlled
trial of the vaccine among HIV-infected adults, conducted
in Uganda, showed no efficacy against invasive pneumo-
coccal disease and an inexplicable increase in the risk of
all cause pneumonia among vaccine recipients [22,23].
Given the disparate results of earlier studies of the effec-
tiveness of the pneumococcal polysaccharide vaccine
among HIV-infected persons, we were interested in assess-
ing its effectiveness among this patient population in São
Paulo, Brazil. Because it would be considered unethical to
conduct a randomized placebo-controlled trial of a vac-
cine that is now considered standard of care, we con-
ducted an observational study, using a case-control
approach [24].
Methods
Participating Institutions and Case Findings
Between November, 2000 and August, 2004, we identi-
fied invasive S. pneumoniae infections among HIV-
infected adults receiving clinical care at the seven largest
public health referral services for HIV/AIDS in São Paulo
City and Campinas (60 km from São Paulo City). At these
institutions (Emilio Ribas Institute, HIV/AIDS Referral
and Training Centre (CRT), Clinical Hospital of Univer-
sity of São Paulo Medical School (HC FMUSP), Clinical
Hospital of University of Campinas (HC UNICAMP),
Hospital of São Paulo State Employee (HSPE) and Casa
da AIDS of the University of São Paulo, all patients with
documented HIV-infection receive care from special
teams of health professionals in inpatient and outpatient
clinics specifically designated for them. In all of these
institutions, patients have access to comprehensive free
care, including anti-retroviral medications and vaccines.
The facilities include microbiology laboratories employ-
ing routine diagnostic methods. All of the participating
institutions have vaccine services, which are part of a spe-
cial vaccine referral network through which products not
available at the routine immunization services (such as
the pneumococcal polysaccharide) are provided. These
vaccine services maintain separate records in which the
name, age, address, vaccine, number of doses, and infor-
mation on underlying health conditions, including HIV-
infection status, are included.
At each participating institution, an up-to-date database
of HIV-infected patients being followed is maintained.
This database includes patients' names, date(s) of HIV
testing; dates and results of CD4 lymphocyte cell counts;
demographic data; and other clinical information.
Over the course of the three year study period, all HIV-
infected patients being followed at one of the participat-
ing institutions who developed a laboratory-confirmed
invasive pneumococcal infection (i.e. recovery of S. pneu-
moniae from a normally sterile body site) were identified
by the clinical microbiology laboratory. In all instances,
the decision to test a patient for the presence of S. pneu-
moniae or other bacterial agents (i.e. to order a culture)
was made by the patient's physician(s) during the clinical
management of the patient.
Study Subjects
Cases
A case was defined as any HIV-infected individual over 18
years of age with invasive pneumococcal disease, defined
as recovery of S. pneumoniae from a normally sterile site
(e.g. from blood, pleural fluid, spinal fluid, or pericardial
fluid). Cases had to have had their HIV infection status
confirmed prior to the invasive pneumococcal infection.
Controls
Controls were defined as HIV-infected individuals over 18
years of age, without a history of documented or sus-
pected invasive pneumococcal disease, receiving medical
care at the same institution as the case and matched to the
case by level of CD4 lymphocyte cell count (<200 cells/
mm3; 200 ≤ 499 cells/mm3 and ≥ 500 cells/mm3) meas-
ured during the same month (± 30 days).BMC Infectious Diseases 2007, 7:119 http://www.biomedcentral.com/1471-2334/7/119
Page 3 of 7
(page number not for citation purposes)
Subject Enrollment
For each potentially eligible case, the patient's clinical
provider was asked to seek the patient's permission to be
approached by the research staff. If the patient agreed, he/
she received a detailed explanation about the study and
signed a written informed consent prior to enrollment in
the study. If the patient had died or was not mentally com-
petent to give informed consent, consent was requested
from the patient's next of kin or the individual who had
legal authority to consent on behalf of the patient.
For each case enrolled in the study, we attempted to iden-
tify four possible control subjects, based on a list of CD4
cell counts generated by the laboratory at each institution.
From the list of potential controls, four were randomly
selected; enrollment procedures were identical to those
used for cases. Potential control subjects who agreed to be
contacted were called and arrangements were made to
meet them at their next regularly scheduled outpatient
visit, at which time written informed consent was
obtained.
The study protocol was approved by the Institutional
Review Boards at the University of California, Berkeley
and at the institutions where cases and controls were
selected, as well as the Brazilian National Ethical Commit-
tee.
Data Collection
We interviewed patients (or next of kin) and abstracted
data from medical records, laboratory records, and vacci-
nation service files. The interview was administered by a
trained interviewer using a structured questionnaire with
questions concerning level of education; measures of
socio-economic status and household crowding; previous
hospitalization(s) with pneumonia, sexual behavior and
injection drug use; contact with children; and history of
vaccination. Medical and laboratory records were
reviewed and information concerning clinical, demo-
graphic and behavioral characteristics, such as mode of
HIV transmission, co-morbid conditions, markers of dis-
ease progression, use of antiretroviral therapy and receipt
of antimicrobial prophylaxis and vaccines was collected.
Vaccine exposure was assessed by patient interview,
review of medical records, and review of records from the
adult vaccination service, which records all vaccinations
given to adults.
Laboratory Methods
The Instituto Adolfo Lutz, the public health referral labo-
ratory of the São Paulo State Health Department, con-
firmed the identification of S. pneumoniae isolates and
performed the serotyping. The identification and serotyp-
ing of S. pneumoniae was done using the Quellung reac-
tion, based on serotype-specific anti-capsular
polysaccharide antisera produced by the Statens Serum
Institut, Copenhagen.
Statistical Analysis
To examine the association between prior receipt of pneu-
mococcal polysaccharide vaccine and the development of
invasive pneumococcal disease, matched bivariate analy-
ses were performed using conditional logistic regression.
Matched odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated. Risk factors and potential con-
founders for invasive pneumococcal disease were deter-
mined a priori. Potential confounders examined included
demographic variables, educational level, smoking and
alcohol use, injection drug use (IDU), report of a previous
hospitalization with pneumonia; close contact with a
child in the prior four weeks; history of pulmonary tuber-
culosis and antiretroviral use at the last visit. Vaccine effi-
cacy was calculated as 1-OR [24]. All statistical analyses
were performed using Stata version 8 (Stata Corp, College
Station, Texas).
Results
During the study interval, cultures from sterile sites posi-
tive for S. pneumoniae were identified from 99 HIV-
infected patients 18 years old or greater. We were able to
include 79 (80%) of these patients in our study. Of the 20
patients not included in the study, two had HIV-infection
identified concurrently with the diagnosis of invasive
pneumococcal disease and thus had not previously had
their CD4+ T cell counts measured and were not eligible
for enrollment; two were homeless and were lost to fol-
low-up; and in one case the family refused to give consent.
The other 15 patients received care only in the emergency
room; were not registered at the institutions; and did not
return for follow-up care. No age or gender differences
were found between the 79 cases included and the 20 not
included in the present study (data not shown). An aver-
age of three matched controls (range 1–4) could be iden-
tified and enrolled for each case. In total there were 242
controls. Among the 79 cases, bacteremia was the most
common clinical manifestation (n = 69, 87%), followed
by meningitis (n = 7, 9%). Of the 79 cases, 15 died, 13 of
them with bacteremia and 2 due to meningitis.
As expected, the cases and controls had similar CD4 cell
counts (median = 160 cells/ml3 for cases, 174 cells/ml3
controls). Age, gender, and race did not differ among cases
and controls (Table 1). Among the socio-economic and
demographic risk factors examined, invasive pneumococ-
cal infection was associated with having had less educa-
tion and living in sub-standard housing (i.e. being
homeless or living in a "slum"). Other risk factors for
invasive pneumococcal infection included alcohol con-
sumption, injection drug use, close contact with children
under the age of 10 years in the previous four weeks, andBMC Infectious Diseases 2007, 7:119 http://www.biomedcentral.com/1471-2334/7/119
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a history of previous hospitalization for pneumonia. Use
of anti-retroviral medication and receipt of pneumococcal
polysaccharide vaccine were each associated with a
decreased risk of invasive pneumococcal infection on
bivariate analysis. Among vaccinated individuals, the
duration time between vaccination and infection (cases)
or enrolment (controls) ranged from 35 to 988 days. The
vaccine effectiveness was 63% (95% CI: 28%-81%).
In the multivariate analysis, close contact with a child,
injection drug use, and previous hospitalization for pneu-
monia, were still associated with an increased risk of inva-
sive pneumococcal infection (adjusted odds ratios of 3.22
(95% CI 1.60-6.48, 2.43 [95% CI: 1.13-5.23], and 2.23
[95% CI: 1.16-4.30], respectively). Ever having pulmo-
nary tuberculosis was no longer associated with an
increased risk for invasive pneumococcal infection (Table
2). Being on anti-retroviral therapy at the time of the last
outpatient visit was consistently associated with a
decreased risk of invasive pneumococcal infection (OR =
0.27; 95% CI: 0.12 – 0.59). After controlling for the other
variables included in the conditional logistic regression
model, receipt of pneumococcal polysaccharide vaccine
was no longer associated with a reduced odds of invasive
pneumococcal disease. (OR = 0.82, 95% CI: 0.38 – 1.77).
It is worthwhile to mention that the inclusion of demo-
Table 1: Characteristics of Study Participants
Characteristic Cases (79)* n % Controls (242)* N % OR Crude 95% C.I.
Age (yrs)
≤ 38 42 (53.16) 131 (54.13) 1.0 0.64 – 1.76
≥ 39 37 (46.84) 111 (45.87) 1.06
Gender
Female 30 (37.97) 88 (36.36) 1.0 0.58 – 1.60
Male 49 (62.03) 154 (63.64) 0.96
Education
University 5 (6.94) 42 (17.57) 1.0
High 18 (25.00) 81 (33.89) 1.89 0.64 – 5.55
Middle 22 (30.56) 61 (25.52) 3.07 1.05 -9.00
Elementary 27 (37.50) 54 (22.94) 5.18 1.72 – 15.57
Illiterate 0 (0.00) 1 (0.42) -- --
Race/Ethnicity
White 48 (61.54) 156 (67.24) 1.0 0.73 – 2.16
"Non-White" 30 (38.46) 76 (32.76) 1.25
Housing
Standard 61 (81.33) 228 (94.61) 1.0 1.78 – 9.94
Substandard 14 (18.67) 13 (5.39)' 4.20
Ever smoked
No 22 (31.88) 105 (42.98) 1.0 0.85 -2.72
Yes 47 (68.12) 137 (57.02) 1.52
Alcohol consumption
No 63 (79.75) 221 (91.32) 1.0 1.42 – 5.86
Yes 16 (20.25) 21 (8.68) 2.88
Injection drug user
No 50 (69.44) 208 (87.03) 1.0 1.48 – 5.28
Yes 22 (30.56) 31 (12.97) 2.79
Close contact w/child
No 38 (52.78) 176 (87.03) 1.0 1.53 – 5.14
Yes 34 (30.56) 66 (12.97) 2.81
Prev. hosp w/pneumonia
No 41 (56.94) 191 (78.93) 1.0 1.58 – 4.98
Yes 31 (43.06) 51 (21.07) 2.80
ARV** at the last visit
No 28 (35.44) 34 (14.05) 1.0 0.14 – 0.49
Yes 51 (64.56) 208 (85.95) 0.26
Received pneumo vaccine
No 65 (82.28) 157 (64.88) 1.0 0.19 – 0.72
Yes 14 (17.72) 85 (31.12) 0.37'
*Differences in numbers are due to missing data for specific variables
**ARV: Antiretroviral therapyBMC Infectious Diseases 2007, 7:119 http://www.biomedcentral.com/1471-2334/7/119
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graphic and socio-economic variables in the model did
not change the measure of association (OR = 0.82; 95%
CI: 0.33 – 2.04) (data not shown).
Of the 79 patients included in the case-control study, S.
pneumoniae isolates from 47 were available for serotyp-
ing. Of these 47 isolates, 40 (85%) were of serotypes
included in the 23 valent pneumococcal polysaccharides
vaccine. (Table 3). All 11 isolates from previously vacci-
nated cases were of serotypes included in the vaccine, as
were 29 (80%) of the 36 isolates from unvaccinated cases.
A sub-analysis limited to cases caused by serotypes
included in the vaccine showed no evidence of a protec-
tive effect (data not shown).
Discussion
The effectiveness of pneumococcal purified polysaccha-
ride vaccines in immunosuppressed individuals has been
the subject of controversy for many years. One review and
meta-analysis of the results of randomized controlled tri-
als of pneumococcal polysaccharide vaccine effectiveness
reported that while the vaccine was approximately 84%
effective against pneumococcal pneumonia and 82%
effective against pneumococcal bacteremia among immu-
nocompetent individuals, it did not reduce the risk of
pneumococcal pneumonia, pneumococcal bacteremia, or
pneumonia deaths among those likely to have an
impaired immune system [25]. Furthermore, the only ran-
domized controlled trial of the vaccine among HIV-
infected individuals (who were not receiving anti-retrovi-
ral therapy) not only failed to demonstrate any efficacy of
the vaccine, but unexpectedly found an increased risk of
all-cause pneumonia in the vaccinated group compared to
those given placebo [22]. Longer term follow up of study
participants confirmed the excess of all-cause pneumonias
in the vaccinated group, but nevertheless found suggestive
evidence of a reduced risk of all cause mortality among
vaccine recipients [23]. Recent findings of a retrospective
cohort study carried out between 1998 and 2001, in
Washington State, USA, and of a case-control study con-
ducted in Catalonia, Spain between 2001–02 supported
prior studies demonstrating the effectiveness of the vac-
cine for the prevention of bacteremia among the elderly
[11,12]. A recently published observational cohort study
of HIV-infected individuals in Baltimore, Maryland did
not find an association between receipt of pneumococcal
vaccination and a reduced risk of invasive pneumococcal
disease [21].
In general, randomized, placebo-controlled trials of pneu-
mococcal polysaccharide vaccines among HIV-infected
individuals have been judged to be not feasible in many
countries for a variety of ethical and scientific reasons. As
a result, most evaluations of the effectiveness of the vac-
cine among HIV-infected individuals have been con-
ducted using observational study designs, including both
case-control studies and cohort studies [13-19,21]. These
Table 3: Pneumococcal serotype distribution according to 
vaccination status
Serotype Vaccination status
Vaccine-serotypes Non-vaccinated Vaccinated
12 2
32 1
50 1
6B 5 2
7F 2 0
9N 0 1
9V 7 1
10A 2 1
11A 2 0
14 2 1
17F 1 0
19A 1 0
19F 1 1
23F 2 0
Total vaccine serotypes 29 11
Non-vaccine serotypes
6A 1 0
10F 1 0
13 1 0
18A 1 0
23B 1 0
Total non-vaccine serotypes 7 0
Non-typed
G1 0
I1 0
Total 36 11
Table 2: Selected risk factors for invasive pneumococcal disease in a multivariate (conditional logistic) regression model
Characteristic Crude OR (95% C.I.) Adjusted OR (95% C.I.)
Pulmonary Tb ever 2.54 (1.43 – 4.50) 1.95 (0.95 – 4.03)
Close contact with child 2.81 (1.53 – 5.14) 3.22 (1.60 – 6.48)
Injection drug use 2.79 (1.48 – 5.28) 2.43 (1.13 – 5.23)
Previous hospitalization with pneumonia 2.80 (1.58 – 4.98) 2.23 (1.16 – 4.30)
Antiretroviral therapy at the last visit 0.26 (0.14 – 0.49) 0.27 (0.12 – 0.59)
Had received pneumococcal polysaccharide vaccine 0.37 (0.19 – 0.72) 0.82 (0.38 – 1.77)BMC Infectious Diseases 2007, 7:119 http://www.biomedcentral.com/1471-2334/7/119
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studies, which have primarily focused on the vaccine's
effectiveness in preventing invasive S. pneumoniae infec-
tions (rather than pneumonia), have produced a wide
range of estimates, from 0% to 86%, but at least some of
this variation appears to have been due to differences in
the level of immunosuppression present in the HIV-
infected individuals included in the studies. In individuals
with higher CD4 T cell counts and/or receiving effective
anti-retroviral regimens, the estimates of the effectiveness
of pneumococcal polysaccharide vaccine have typically
been in the range of 40 to 80%. On the other hand, there
is no evidence from previous studies that the vaccine is
effective in severely immunocompromised HIV-infected
individuals.
Because Brazil has been at the forefront of making effec-
tive anti-retroviral drug regimens available to HIV-
infected individuals, irrespective of their ability to pay, the
patient population from which our cases and controls
came typically were receiving anti-retroviral drugs if indi-
cated under Brazil's guidelines for the care of patients with
HIV/AIDS. We found that being on anti-retroviral medica-
tions at the time of the last outpatient visit was associated
with substantial protection against invasive pneumococ-
cal infection.
Conclusion
In this patient population, we were unable to demonstrate
that pneumococcal polysaccharide vaccine was protective
against invasive pneumococcal infection. While the vac-
cine is relatively inexpensive and safe, its effectiveness
among HIV-infected adults is uncertain and the argument
in favor of giving it routinely to such patients is not sup-
ported by consistent evidence of its effectiveness. If given
to such patients, however, it should be given before
advanced immunosuppression has developed, in order to
maximize the likelihood that it will be effective.
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